

Cancer as a Metabolic Disease

On the Origin, Management,
and Prevention of Cancer



Thomas N. Seyfried

Cancer as a Metabolic Disease

Cancer as a Metabolic Disease

On the Origin, Management and Prevention of Cancer

Thomas N. Seyfried

 **WILEY**

A John Wiley & Sons, Inc., Publication

Copyright © 2012 by John Wiley & Sons, Inc. All rights reserved

Published by John Wiley & Sons, Inc., Hoboken, New Jersey
Published simultaneously in Canada

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at <http://www.wiley.com/go/permission>.

Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor author shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

For general information on our other products and services or for technical support, please contact our Customer Care Department within the United States at (800) 762-2974, outside the United States at (317) 572-3993 or fax (317) 572-4002.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic formats. For more information about Wiley products, visit our web site at www.wiley.com.

Library of Congress Cataloging-in-Publication Data:

Seyfried, Thomas N., 1946–

Cancer as a metabolic disease : on the origin, management, and prevention
of cancer / by Thomas N. Seyfried.

p. ; cm.

Includes bibliographical references and index.

ISBN 978-0-470-58492-7 (cloth)

I. Title.

[DNLM: 1. Neoplasms–diet therapy. 2. Neoplasms–metabolism. 3. Energy
Metabolism. 4. Ketogenic Diet. 5. Mitochondria–metabolism. QZ 200]

616.99'40654–dc23

2011049798

Printed in the United States of America

10 9 8 7 6 5 4 3 2 1

*This book is dedicated to the millions of people who have suffered
and died from toxic cancer therapies*

Contents

Forword	xiii	
Preface	xv	
1. Images of Cancer		1
How Cancer is Viewed	2	
References	13	
2. Confusion Surrounds the Origin of Cancer		15
The Oncogenic Paradox	18	
Hallmarks of Cancer	18	
Reassessment	26	
References	27	
3. Cancer Models		31
Problems with Some Cancer Models	31	
Animal Charges as a Major Impediment to Cancer Research	38	
Problems with Tumor Histological Classification	39	
Personal Perspective on Cancer	44	
References	45	
4. Energetics of Normal Cells and Cancer Cells		47
Metabolic Homeostasis	47	
The Constancy of the $\Delta G'_{\text{ATP}}$	54	
ATP Production in Normal Cells and Tumor Cells	55	
Energy Production Through Glucose Fermentation	57	
Glutaminolysis with or without Lactate Production	61	
Transamination Reactions	64	
TCA Cycle, Substrate-Level Phosphorylation	66	
Cholesterol Synthesis and Hypoxia	67	
Summary	67	
References	68	

5. Respiratory Dysfunction in Cancer Cells	73
Normal Mitochondria	74
Morphological Defects in Tumor Cell Mitochondria	77
Proteomic Abnormalities in Tumor Cell Mitochondria	79
Lipidomic Abnormalities in Tumor Cell Mitochondria	81
Cardiolipin: A Mitochondrial-Specific Lipid	83
Cardiolipin and Abnormal Energy Metabolism in Tumor Cells	85
Complicating Influence of the In Vitro Growth Environment on Cardiolipin Composition and Energy Metabolism	92
Mitochondrial Uncoupling and Cancer	97
Cancer Cell Heat Production and Uncoupled Mitochondria	98
Personal Perspective	99
Summary	100
References	101
6. The Warburg Dispute	107
Sidney Weinhouse's Criticisms of the Warburg Theory	108
Alan Aisenberg's Criticisms of the Warburg Theory	110
Sidney Colowick's Assessment of the Aisenberg Monograph	113
Apples and Oranges	114
References	116
7. Is Respiration Normal in Cancer Cells?	119
Pseudo-Respiration	119
How Strong is the Scientific Evidence Showing that Tumor Cells can Produce Energy Through OxPhos?	124
OxPhos Origin of ATP in Cancer Cells Reevaluated	124
What About OxPhos Expression in Other Tumors?	127
The Pedersen Review on Tumor Mitochondria and the Bioenergetics of Cancer Cells	128
References	129
8. Is Mitochondrial Glutamine Fermentation a Missing Link in the Metabolic Theory of Cancer?	133
Amino Acid Fermentation can Maintain Cellular Energy Homeostasis During Anoxia	133
Evidence Suggesting that Metastatic Mouse Cells Derive Energy from Glutamine Fermentation	134
Fermentation Energy Pathways can Drive Cancer Cell Viability Under Hypoxia	138
Competing Explanations for the Metabolic Origin of Cancer	141
Chapter Summary	143
References	143

9. Genes, Respiration, Viruses, and Cancer 145

Does Cancer have a Genetic Origin?	145
Respiratory Insufficiency as the Origin of Cancer	150
Germline Mutations, Damaged Respiration, and Cancer	154
Somatic Mutations and Cancer	158
Revisiting the Oncogene Theory	160
Mitochondrial Mutations and the Absence or Presence of Cancer	163
Viral Infection, Damaged Respiration, and the Origin of Cancer	165
Summary	168
References	168

10. Respiratory Insufficiency, the Retrograde Response, and the Origin of Cancer 177

The Retrograde (RTG) Response: An Epigenetic System Responsible for Nuclear Genomic Stability	177
Inflammation Injures Cellular Respiration	181
Hypoxia-Inducible Factor (HIF) Stability is Required for the Origin of Cancer	182
Mitochondria and the Mutator Phenotype	183
Calcium Homeostasis, Aneuploidy, and Mitochondrial Dysfunction	186
Mitochondrial Dysfunction and Loss of Heterozygosity (LOH)	187
Tissue Inflammation, Damaged Respiration, and Cancer	188
References	189

11. Mitochondria: The Ultimate Tumor Suppressor 195

Mitochondrial Suppression of Tumorigenicity	195
Normal Mitochondria Suppress Tumorigenesis in Cybrids	196
Evidence from ρ^0 Cells	198
Normal Mitochondria Suppress Tumorigenesis In Vivo	199
Normal Mouse Cytoplasm Suppresses Tumorigenic Phenotypes	200
Enhanced Differentiation and Suppressed Tumorigenicity in the Liver Microenvironment	202
Summary of Nuclear-Cytoplasmic Transfer Experiments	203
References	204

12. Abnormalities in Growth Control, Telomerase Activity, Apoptosis, and Angiogenesis Linked to Mitochondrial Dysfunction 207

Growth Signaling Abnormalities and Limitless Replicative Potential	208
Linking Telomerase Activity to Cellular Energy and Cancer	209
Evasion of Programmed Cell Death (Apoptosis)	209
Sustained Vascularity (Angiogenesis)	210
References	211

13. Metastasis	215
Metastasis Overview	215
Cellular Origin of Metastasis	217
Macrophages and Metastasis	221
Carcinoma of Unknown Primary Origin	232
Many Metastatic Cancers Express Multiple Macrophage Properties	233
Linking Metastasis to Mitochondrial Dysfunction	233
Revisiting the “Seed and Soil” Hypothesis of Metastasis	235
Revisiting the Mesenchymal Epithelial Transition (MET)	236
Genetic Heterogeneity in Cancer Metastases	237
Transmissible Metastatic Cancers	240
The Absence of Metastases in Crown-Gall Plant Tumors	240
Chapter Summary	241
References	241
14. Mitochondrial Respiratory Dysfunction and the Extrachromosomal Origin of Cancer	253
Connecting the Links	254
Addressing the Oncogenic Paradox	255
Is Cancer Many Diseases or a Singular Disease of Energy Metabolism?	258
References	258
15. Nothing in Cancer Biology Makes Sense Except in the Light of Evolution	261
Revisiting Growth Advantage of Tumor Cells, Mutations, and Evolution	262
Tumor Cell Fitness in Light of the Evolutionary Theory of Rick Potts	269
Cancer Development and Lamarckian Inheritance	271
Can Teleology Explain Cancer?	272
References	272
16. Cancer Treatment Strategies	277
Current Status of Cancer Treatment	277
The “Standard of Care” for Glioblastoma Management	280
References	285
17. Metabolic Management of Cancer	291
Is it Dietary Content or Dietary Composition that Primarily Reduces Tumor Growth?	292
Dietary Energy Reduction and Therapeutic Fasting in Rodents and Humans	294

Ketogenic Diets	295
Glucagon and Insulin	297
Basal Metabolic Rate	298
Ketones and Glucose	298
Metabolic Management of Brain Cancer Using the KD	299
Glucose Accelerates Tumor Growth!	301
Glucose Regulates Blood Levels of Insulin and Insulin-Like Growth Factor 1	302
Dietary Energy Reduction is Antiangiogenic	302
Dietary Energy Reduction Targets Abnormal Tumor Vessels	307
Dietary Energy Reduction is Proapoptotic	309
Dietary Energy Reduction is Anti-Inflammatory	310
Targeting Energy Metabolism in Advanced Cancer	314
Differential Response of Normal Cells and Tumor Cells to Energy Stress	316
Dietary Energy Reduction is Anti-Invasive in Experimental Glioblastoma	318
Influence of Growth Site and Host on Tumor Progression	322
Implications of Dietary Energy Reduction for Anticancer Therapeutics	324
Targeting Glucose	325
Metformin	326
Synergistic Interaction of the Restricted Ketogenic Diet (KD-R) and 2-Deoxyglucose (2-DG)	327
Can Synergy Occur with the KD-R and Hyperbaric Oxygen Therapy?	331
Targeting Glutamine	333
Glutamine Targeting Inhibits Systemic Metastasis	334
Targeting Phagocytosis	339
Targeting the Microenvironment	340
Dietary Energy Reduction as a Mitochondrial Enhancement Therapy (MET)	341
Summary	341
References	341

18. Patient Implementation of Metabolic Therapies for Cancer Management

355

Introduction	355
Guidelines for Implementing the Restricted Ketogenic Diet as a Treatment Strategy for Cancer	356
Complicating Issues for Implementing the KD-R as a Treatment Strategy for Cancer	366
Radiation and Chemotherapy is a Standard Treatment for Many Malignant Cancers	366
Compliance	367

xii Contents

Cancer as a Genetic Disease	367
Mechanism of Action?	368
Cachexia	368
Summary	369
References	370

19. Cancer Prevention **375**

Cell Phones and Cancer	376
Alzheimer's Disease and Cancer Risk	377
Ketone Metabolism Reduces Cancer Risk	378
Mitochondrial Enhancement Therapy	379
Therapeutic Fasting and Cancer Prevention	379
Autophagy and Autolytic Cannibalism: A Thermodynamic Approach to Cancer Prevention	381
Cancer Prevention by Following Restricted Ketogenic Diet	382
References	384

20. Case Studies and Personal Experiences in Using the Ketogenic Diet for Cancer Management **387**

Effects of a Ketogenic Diet on Tumor Metabolism and Nutritional Status in Pediatric Oncology Patients: Comments from Dr. Linda Nebeling	387
Raffi's Story: Comments from Miriam Kalamian	389
Biological Plausibility that Cancer is a Metabolic Disease Dependent for Growth on Glucose and Glutamine: Comments from Dr. Bomar Herrin	395
Using the Restricted Ketogenic Diet for Brain Cancer Management: Comments from Neuro-Oncologist, Dr. Kraig Moore	397
The Ketogenic Diet for Brain Cancer Management: Comments from Beth Zupec-Kania	400
Summary	402
References	403

21. Conclusions **405**

Major Conclusions	407
References	408

Index 409

Foreword

Cancer persists as a major disease of mortality and is afflicting more people today than ever before. Few families remain untouched by this insidious and vicious disease. In fact, cancer is predicted to overtake heart disease as the prime cause of death in industrialized societies during this century. I have worked in the cancer metabolism field since the late 1960s and have extensively published works on the metabolic basis and properties of cancer. While I do not know Dr. Seyfried personally, I am very impressed with the excellent job he has done in highlighting abnormal energy metabolism as the central issue of the cancer problem. I recognized long ago the pivotal role of mitochondria and of aerobic glycolysis in sustaining and promoting cancer growth. The Nobel laureate, Otto Warburg, was the first to provide evidence during the early part of the last century for the involvement of disturbed respiration with compensatory fermentation (glycolysis) as a common property of cancer, thus perceived to be related to its uncontrolled growth and progression. Few subjects have been as controversial in the cancer field as Otto Warburg and his theory of cancer. It is nice to see how Seyfried shows that Warburg was largely correct in defining the nature of the disease as involving insufficient respiration with compensatory fermentation. I knew personally many of the key figures and their research mentioned in Seyfried's book, including Dean Burk, Peter Mitchell, Sidney Weinhouse, and my former Department Chair, Albert Lehninger, among others. Nevertheless, there were times in my early career when I felt almost alone in considering energy metabolism as important to the cancer problem. I even remember one of my colleagues, an expert in DNA technology, dumping Lehninger's "Warburg Flasks" in the trash as relics of a bygone era in cancer research. Fortunately for him, Lehninger was no longer the Department Chair, and fortunately for me, I salvaged many of these flasks and am now glad I did. After reading Seyfried's book, I think these flasks will become valuable as collector items.

The cancer field went seriously off course during the mid-1970s when many investigators began considering cancer as primarily a genetic disease rather than as a metabolic disease. The metabolic defects in cancer cells were thought to arise as secondary consequences of genomic instability. Seyfried provides substantial evidence documenting the inconsistencies of the gene "only" theory. He critically reevaluates the evidence linking cancer progression to a Darwinian process and raises the intriguing possibility that cancer progression is an example of Lamarckian evolution. When viewed collectively, the documented inconsistencies of the gene

“only” theory make it clear why little progress has been made in the cancer war and in the development of effective nontoxic therapies. A key point made by Seyfried is that most of the genomic instability seen in cancer likely arises as a consequence rather than as the cause of the disease. When viewed more as a metabolic disease, many cost effective therapeutic strategies become recognized for cancer management. I know this first hand from our studies of 3-bromopyruvate (3BP), discovered in my laboratory by Dr. Young Ko, as a potent anticancer agent. This is a low cost drug with powerful and quick antitumor effects against multiple cancers in animal models and in cancer patients. 3BP works primarily by targeting tumor cell energy metabolism, thus depleting the energy-rich compound “ATP” essential for growth. At the effective doses used, it does this without toxicity to normal cells. Seyfried’s book provides substantial evidence showing how cancer can be managed using various other drugs and diets that target energy metabolism. In addition, the restriction of glucose and glutamine, which drive cancer energy metabolism, cripples the ability of cancer cells to replicate and disseminate. The gene theory has deceived us into thinking that cancer is more than a single disease. Certainly, tumors do not all grow at the same rate. Nevertheless, cancer is a singular disease involving aberrant energy metabolism as Warburg originally showed and as I, and more recently many others, have documented in biochemical studies. Seyfried drives home this message throughout his book.

Seyfried’s treatise refocuses attention on the central issue of cancer as a metabolic disease according to Warburg’s original theory. The book is unique in linking nearly all aspects of the disease to respiratory insufficiency with compensatory fermentation. Cancer has remained incurable for many due largely to a general misunderstanding of its origin, biology, and metabolism. Hopefully, Seyfried’s thoughtful analysis of the “cancer problem” will change our understanding of the disease and move the field in the right direction toward solutions and therapies, such as 3BP, that act much faster and more effectively than those currently available.

DR. PETER PEDERSEN
Professor of Biological Chemistry
Johns Hopkins University School of Medicine
Baltimore, MD

Preface

Cancer persists as a plague in modern society. The lack of progress in either managing or preventing cancer motivated me to write this treatise. I am a biochemical geneticist and have worked on the lipid biochemistry of cancer since the early 1980s. I have developed numerous mouse models for brain tumors and for systemic metastatic cancer. Several major findings planted the seed for this treatise. First, it became clear to me that the therapeutic action of some anticancer drugs operated largely through reduced caloric intake. Second, that reduced caloric intake could target the majority of cancer hallmarks. Third, that ketone bodies can serve as an alternative fuel to glucose in most cells with normal respiratory function. Fourth, that metastatic cancer arises from cells along macrophage lineage. Fifth, that all cancer cells regardless of tissue origin express a general defect in mitochondrial energy metabolism. Finally, that cancer can be effectively managed and prevented once it becomes recognized as a metabolic disease.

In recognizing cancer as a metabolic disease, it gradually became clear to me why so many people die from the disease. Many of the current cancer treatments exacerbate tumor cell energy metabolism, thus allowing the disease to progress and eventually become unmanageable. Most cancer patients do not battle their disease but are offered toxic concoctions that can eventually undermine their physiological strength and their will to resist. Cancer treatments are often feared as much as the disease itself. The view of cancer as a genetic disease has confounded the problem and is largely responsible for the failure to develop effective therapies. The view of cancer as a genetic disease is based on the flawed notion that somatic mutations cause cancer. Substantial evidence indicates that genomic instability is linked to protracted respiratory insufficiency. Once cancer becomes recognized as a metabolic disease with metabolic solutions, more humane and effective treatment strategies will emerge. My treatise highlights cancer as a metabolic disease and identifies the inconsistencies of the gene theory of cancer. Moreover, my treatise addresses most of the so-called provocative questions raised by the National Cancer Institute regarding outstanding issues in cancer research. This treatise lays the foundation for the eventual resolution of the disease.

I would like to thank my many students and colleagues for helping me in producing the data and in developing the concepts for this treatise. I thank my former graduate students Mary Louise Roy (MS, 1987), Michelle Cottericho (MS, 1992), Mohga El-Abbadi (PhD, 1995), Hong Wei Bai (PhD, 1996), John Brigande (BS, 1989; MS, 1992; PhD, 1997), Jeffrey Ecsedy (PhD, 1998), Mark Manfredi

(PhD, 1999), Michaela Ranes (BS, 1998; MS, 2000), Dia Banerjee (MS, 2001), Michael Drage (MS, 2006), Christine Denny (BS, 2005; MS, 2006), Weihua Zhou (MS, 2006), Laura Abate (PhD, 2006), Michael Kiebish (PhD, 2008), Leanne Huy-sentruyt (PhD, 2008), John Mantis (PhD, 2010), and Laura Shelton (PhD, 2010). I would also like to acknowledge my current students Linh Ta and Zeynep Akgoc for their continued productivity. I would also like to thank the following undergraduate students for their input and help, including Katherine Holthause, Jeremy Marsh, Jeffery Ling, Will Markis, Tiernan Mulrooney, Todd Sanderson, Todd Theman, Lisa Mahoney, Michelle Levine, Emily Coggins, Erin Wolfe, Ivan Urits, Taryn LeRoy, and Emily Gaudiano. I would like to thank those students from my BI503 class on *Current Topics in Cancer Research* for their input.

I would like to thank faculty colleagues in the Boston College Biology Department, including Drs. Thomas Chiles, Fr. Richard McGowan SJ, and Jeffery Chuang. I would like to thank Dr. Robert K. Yu, Dr. James Fox and my son Dr. Nicholas T. Seyfried for technical assistance. I would like to thank Avtar Roopa for provocative discussion. I would like to thank the late Drs. Sanford Palay, Harry Zimmerman, and Allan Yates for their encouragement and assistance. I would also like to give special acknowledgement to Dr. Purna Mukherjee and Roberto Flores. Purna was the first to make me aware of the powerful therapeutic action of calorie restriction. She is superbly trained in the areas of angiogenesis and inflammation and her work provided seminal information on the mechanisms by which dietary energy reduction can both treat and prevent cancer. Roberto Flores is exceptional in his dedication to finding the truth underlying the metabolic origin of cancer and in questioning the metabolic origin of cancer. Finally, I would like to thank my institution, Boston College, for providing animal care support over the first 23 years of my employment there (1985–2008). The data collected supporting my treatise would not have been possible without this invaluable institutional support. This support was consistent with the Ignatian philosophy of service to others.




Figure 1.2 See full caption on page 4.



Figure 1.5a See full caption on page 7.



Figure 1.5d See full caption on page 7.



Figure 1.6 See full caption on page 7.




Figure 1.7 See full caption on page 8.



Figure 1.8 See full caption on page 8.



Figure 1.13 See full caption on page 11.